ALT
Price
$4.08
Change
-$0.03 (-0.73%)
Updated
Jul 25 closing price
Capitalization
330.92M
12 days until earnings call
INMB
Price
$2.71
Change
-$0.07 (-2.52%)
Updated
Jul 25 closing price
Capitalization
73.82M
4 days until earnings call
Interact to see
Advertisement

ALT vs INMB

Header iconALT vs INMB Comparison
Open Charts ALT vs INMBBanner chart's image
Altimmune
Price$4.08
Change-$0.03 (-0.73%)
Volume$2.97M
Capitalization330.92M
INmune Bio
Price$2.71
Change-$0.07 (-2.52%)
Volume$1.34M
Capitalization73.82M
ALT vs INMB Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. INMB commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and INMB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (ALT: $4.08 vs. INMB: $2.71)
Brand notoriety: ALT and INMB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 55% vs. INMB: 28%
Market capitalization -- ALT: $330.92M vs. INMB: $73.82M
ALT [@Biotechnology] is valued at $330.92M. INMB’s [@Biotechnology] market capitalization is $73.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileINMB’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • INMB’s FA Score: 0 green, 5 red.
According to our system of comparison, both ALT and INMB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while INMB’s TA Score has 4 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • INMB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALT is a better buy in the short-term than INMB.

Price Growth

ALT (@Biotechnology) experienced а 0.00% price change this week, while INMB (@Biotechnology) price change was +11.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ALT is expected to report earnings on Nov 11, 2025.

INMB is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($331M) has a higher market cap than INMB($73.8M). INMB (-41.970) and ALT (-43.412) have similar YTD gains . INMB has higher annual earnings (EBITDA): -41.52M vs. ALT (-90.75M). ALT has more cash in the bank: 150M vs. INMB (19.3M). INMB has less debt than ALT: INMB (347K) vs ALT (1.59M). INMB has higher revenues than ALT: INMB (50K) vs ALT (20K).
ALTINMBALT / INMB
Capitalization331M73.8M449%
EBITDA-90.75M-41.52M219%
Gain YTD-43.412-41.970103%
P/E RatioN/AN/A-
Revenue20K50K40%
Total Cash150M19.3M777%
Total Debt1.59M347K457%
FUNDAMENTALS RATINGS
ALT vs INMB: Fundamental Ratings
ALT
INMB
OUTLOOK RATING
1..100
7850
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
9498
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INMB's Valuation (82) in the Biotechnology industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that INMB’s stock grew similarly to ALT’s over the last 12 months.

INMB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that INMB’s stock grew similarly to ALT’s over the last 12 months.

ALT's SMR Rating (97) in the Miscellaneous Commercial Services industry is in the same range as INMB (99) in the Biotechnology industry. This means that ALT’s stock grew similarly to INMB’s over the last 12 months.

ALT's Price Growth Rating (94) in the Miscellaneous Commercial Services industry is in the same range as INMB (98) in the Biotechnology industry. This means that ALT’s stock grew similarly to INMB’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as INMB (100) in the Biotechnology industry. This means that ALT’s stock grew similarly to INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTINMB
RSI
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PKCOY13.05N/A
N/A
Park 24 Corp.
OJOC335.00N/A
N/A
Ojai Oil Co.
IPSEY32.42-0.58
-1.75%
Ipsen S.A.
SUUFF0.16N/A
-1.78%
STRATHMORE PLUS URANIUM CORP.
ECRTF1.43-0.07
-4.67%
Atex Resources Inc.